Lv4
410 积分 2024-07-10 加入
Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma
1个月前
已完结
First‐line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta‐analysis and cost‐effectiveness analysis
1个月前
已完结
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer
1个月前
已完结
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
1个月前
已完结
Cost–effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
1个月前
已关闭
Cost-effectiveness of nivolumab in patients with NSCLC in the United States
1个月前
已完结
A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
1个月前
已完结
Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma
1个月前
已完结
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
1个月前
已完结
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
